Heart Failure pp 175-181 | Cite as

Heart Failure: Potential Benefit of Growth Hormone Therapy

  • Luigi Saccà
  • Antonio Cittadini
  • Salvatore Longobardi
  • Serafino Fazio
Conference paper


Until a few years ago, growth hormone (GH) was considered essential in the control of linear growth, glucose homeostasis, and skeletal muscle mass. More recently, a series of studies have unequivocally proven that the heart is a target organ for the GH/IGF-I axis, which modulates cardiac structure and function. The importance of the GH/IGF-I axis is also supported by several lines of experimental evidence demonstrating that GH/IGF-I affects the determinants of cardiac output (preload, afterload, and contractility), through direct and indirect mechanisms. The therapeutic options available for the treatment of heart failure are few, and the overall prognosis for this disease remains very poor. Recent studies employing growth factors, which activate myocardial growth by inducing a physiological kind of hypertrophy, seem exciting. In this regard, GH and IGF-I may be the best candidates to produce a growth response in the heart. The large amount of novel information derived from the experimental and clinical studies on GH and cardiac function suggests that this field of research will be an important area of future investigations. Basic research is needed to discover the complex intracellular pathways of GH and IGF-I and to clarify their growth-promoting and positive inotropic actions. Furthermore, survival animal studies employing GH may potentially address whether the beneficial hemodynamic effects of GH in experimental heart failure would translate into a better prognosis for human heart failure.

Key words

Growth hormone Heart Heart failure Dilated cardiomyopathy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    De Boer H, Blok GJ, Van der Veen E (1995) Clinical aspects of growth hormone deficiency in adults. Endocr Rev 16: 63–86PubMedCrossRefGoogle Scholar
  2. 2.
    Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, Poole-Wilson PA, Coats AJS (1997) Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96: 526534Google Scholar
  3. 3.
    Timsit J, Riou B, Bertherat J, Wisnewsky C, Kato NS, Weisberg AS, Lubetzki J, Lecarpentier Y, Winegrad S, Mercadier JJ (1990) Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetic, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle. J Clin Invest 86: 507–515PubMedCrossRefGoogle Scholar
  4. 180.
    L. Saccà et al.Google Scholar
  5. 4.
    Cittadini A, Grossman JD, Napoli R, Katz SE, Strömer H, Smith RJ, Clark R, Morgan JP, Douglas PS (1997) Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am Coll Cardiol 29: 1109–1116PubMedCrossRefGoogle Scholar
  6. 5.
    Mathews LS, Enberg B, Norstedt G (1989) Regulation of rat growth hormone receptor gene expression. J Biol Chem 17: 9905–9910Google Scholar
  7. 6.
    Engelmann GL, Bohem KD, Haskell JF, Khairallah PA, Ilan J (1989) Insulin-like growth factors and neonatal cardiomyocyte development: ventricular gene expression and membrane receptor variations in normotensive and hypertensive rats. Mol Cell Endocrinol 63: 1–14PubMedCrossRefGoogle Scholar
  8. 7.
    Guler H-P, Zapf J, Scheiwiller E, Froesch ER (1988) Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad Sci USA 85: 4889–4893PubMedCrossRefGoogle Scholar
  9. 8.
    D’Ercole AJ, Stiles AD, Underwood LE (1984) Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 81: 935–939PubMedCrossRefGoogle Scholar
  10. 9.
    Cittadini A, Strömer H, Katz SE, Clark R, Moses AC, Morgan JP, Douglas PS (1996) Differential cardiac effects of growth hormone and IGF-I in the rat: a combined in vivo and in vitro evaluation. Circulation 93: 800–809PubMedGoogle Scholar
  11. 10.
    Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J Jr (1995) Insulin-like growth factor I enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 95: 619–627PubMedCrossRefGoogle Scholar
  12. 11.
    Ito H, Hiroe M, Hirata Y, Motoyoshy T, Adachi S, Masayoshi S, Koike A, Nogami A, Marumo F (1993) Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 87: 1715–1721PubMedGoogle Scholar
  13. 12.
    Saccà L, Cittadini A, Fazio S (1994) Growth hormone and the heart. Endocr Rev 15: 555–573PubMedGoogle Scholar
  14. 13.
    Haylor J, Singh I, El Nahas AM (1991) Nitric oxide inhibitor prevents vasodilatation by insulin-like growth factor I. Kidney Int 39: 333–335PubMedCrossRefGoogle Scholar
  15. 14.
    Böger RH, Skamira C, Bode-Boger SM, Brabant G, von Zur Mühlen A, Frölich JC (1996) Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J Clin Invest 98: 2706–2713Google Scholar
  16. 15.
    Cittadini A, Ishiguro Y, Strömer H, Spindler M, Moses AC, Clark R, Douglas PS, Ingwall JS, Morgan JP (1998) Insulin-like growth factor-I but not growth hormone augments mammalian myocardial contractility by sensitising the myofilaments to calcium through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Circ Res 83: 50–59PubMedGoogle Scholar
  17. 16.
    The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 325: 293–302CrossRefGoogle Scholar
  18. 17.
    The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525–533CrossRefGoogle Scholar
  19. 18.
    Packer M, Bristow MR, Cohn JN, Colucci, WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334: 1349–1355PubMedCrossRefGoogle Scholar
  20. 19.
    The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure N Engl J Med 336: 525–533Google Scholar
  21. 20.
    Castagnino HE, Toranzos FA, Milei J, Weiss V, Beigelman R, Sarchi MI, Bordenave CA, Azcoaga R (1992) Preservation of the myocardial collagen framework by human growth hormone in experimental infarction and reduction in the incidence of ventricular aneurysms. Int J Cardiol 35: 101–114PubMedCrossRefGoogle Scholar
  22. 21.
    Jin H, Yang R, Gillet N, Clark R, Ko A, Paoni NF (1995) Beneficial effects of growth hormone and insulin-like growth factor-I in experimental heart failure in rats with chronic ACE inhibition. J Cardiovasc Pharmacol 26: 420–425PubMedCrossRefGoogle Scholar
  23. 22.
    Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, Pardo F, Biondi B, Saccà L (1996) A preliminary study of growth hormone in the treatment of heart failure in patients with dilated cardiomyopathy N Engl J Med 334: 809–814Google Scholar
  24. 23.
    Isgaard J, Bergh CH, Caidhal K, Lomsky M, Hjalmarson A, Bengtsson BA (1998) A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 19: 1704–1711PubMedCrossRefGoogle Scholar
  25. 24.
    Genth-Zotz S, Zotz R, Geil S, Voigtlander T, Meyer J, Darius H (1999) Recombinant growth hormone therapy in patients with ischemic cardiomyopathy effects on hemodinamics, left ventricular function, and cardiopulmonary exercise capacity, Circulation 99: 18–21PubMedGoogle Scholar
  26. 25.
    Osterziel KJ, Styrohm O, Shuler J, Friedrich M, Hanlein D, Willebrock R, Anker SD, Poole-Wilson PA, Ranke MB, Dietz R (1998) Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 351: 1233–1237PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 2000

Authors and Affiliations

  • Luigi Saccà
    • 1
  • Antonio Cittadini
    • 1
  • Salvatore Longobardi
    • 1
  • Serafino Fazio
    • 1
  1. 1.Department of Internal MedicineUniversity Federico II Medical SchoolNaplesItaly

Personalised recommendations